ARTL - Artelo Bio soars 20% on encouraging CBD+TMP data in cancer

Artelo Biosciences (ARTL) rises 20% premarket following data showing potential pharmacodynamic interactions of co-administration of cannabidiol ((CBD)) and tetramethylpyrazine ((TMP)) in cell-based models of cancer.The research focused on the components of Artelo’s CBD:TMP cocrystal program, also known as ART12.11. The researchers found that there were synergistic and additive interactions between CBD and TMP in their abilities to prevent cancer cell growth and to kill cancer cells.However, there was also a small reduction in the anti-migratory effect of CBD when TMP was present.These positive initial studies warrant further in vivo preclinical research in animal tumor models. “The study observed enhanced effects between CBD and TMP, versus either compound alone,"  noted Gregory Gorgas, Artelo’s President & CEO.Full results will be reported at a future scientific conference.

For further details see:

Artelo Bio soars 20% on encouraging CBD+TMP data in cancer